0.79
-1.88%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sihuan Pharmaceutical Holdings Group
Its shares trade on HKEX under the ticker 460.HK. It has been listed since 28 October 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.05bn and net income of CN¥209.4m. At that date it held total assets of CN¥13.56bn and shareholders' equity of CN¥6.82bn.
Sihuan Pharmaceutical Holdings Group Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Beijing, Beijing. The company went IPO on 2010-10-28. The firm is mainly engaged in the research and development, manufacture and sales of pharmaceutical products in China. Its products are applicable in cardio-cerebral vascular (CCV) system, central nervous system, metabolism, oncology and anti-infective fields. Its CCV products include Kelinao, Anjieli and Oudimei, among others. Its non-CCV products include Ren’Ao, Metronidazole and Clindamycin, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Oct 2010
- Employees
- 4,009
- Website
- sihuanpharm.com ↗
Leadership
Pay as last reported
- Dr. Fengsheng CheExecutive Chairman of the Board, since 2006CN¥7.0m
- Dr. Weicheng GuoExecutive Deputy Chairman of the Board, Chief Executive Officer, since 2006CN¥3.0m
- Ms. Guili MiaoDeputy Chief Executive Officer, Chief Financial Officer, Executive Director, since 2022CN¥3.6m
- Ms. Yanling ChenExecutive Director, Joint Company Secretary, since 2018CN¥1.8m
- Dr. Jionglong ZhangExecutive Director, since 2006CN¥657,000
- Mr. Kin Wai LiJoint Company Secretary
- Mr. Wah Kwong TsangNon-Executive Independent DirectorCN¥377,000
- Mr. Guan WangNon-Executive Independent DirectorCN¥275,000
- Mr. Xun ZhuNon-Executive Independent DirectorCN¥377,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 76
- Environment
- 74
- Social
- 99
- Governance
- 55
- Direct emissions (scope 1)
- 34,399.32 t
- Energy emissions (scope 2)
- 49,892.33 t
- Women in the workforce
- 56.77%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sihuan Pharmaceutical Holdings Group Ltd has several notable strengths that contribute to its competitive advantage in the pharmaceutical industry. Firstly, the company has a strong research and development (R&D) division, which enables it to innovate and develop new drugs. This helps Sihuan Pharmaceutical stay ahead of its competitors and offer unique solutions to patients. Additionally, the company has a wide range of product offerings, encompassing various therapeutic areas, giving it a diversified revenue stream.
Weaknesses
- Despite its strengths, Sihuan Pharmaceutical also faces certain weaknesses that hinder its growth potential. One notable weakness is its limited geographical reach. Although the company is well-established in the domestic market, its global presence is relatively limited. Expanding into new markets and establishing a stronger international presence could help mitigate this weakness and tap into untapped potential.
Opportunities
- Sihuan Pharmaceutical operates in an industry with several opportunities for growth and expansion. One major opportunity lies in the aging population worldwide. The increasing prevalence of chronic diseases among the elderly presents a significant market for pharmaceutical companies, including Sihuan. By focusing on developing drugs to address these diseases, the company can tap into this growing market and enhance its revenue stream. Additionally, advancements in technology and digital healthcare solutions offer an opportunity for Sihuan to explore new ways of delivering healthcare services and improving patient outcomes.
Threats
- Alongside opportunities, Sihuan Pharmaceutical also faces various threats that could impact its operations. One prominent threat is the intense competition within the pharmaceutical industry. The presence of large multinational companies and local players poses a challenge to Sihuan's market share and profitability. Additionally, stringent regulations and the lengthy drug approval process can hinder the company's ability to bring new drugs to market quickly. Economic fluctuations, such as currency exchange rate fluctuations, can also impact Sihuan's financial performance and sales in international markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.